FibroBiologics announced that IP Australia accepted its patent application for a method combining fibroblasts, platelet rich plasma, and nucleus pulposus components to regenerate cartilage in degenerated spinal discs. This method aims to restore the cellular environment of healthy discs, potentially improving conditions like chronic lower back pain by rebuilding cartilage rather than just managing symptoms. The patent acceptance extends FibroBiologics' global intellectual property protection for its disc degeneration treatment platform, following a recent European patent grant. This development supports the company's clinical-stage biotech focus on therapies using fibroblast-derived materials.
FibroBiologics' recent patent acceptance provides context for readers interested in biotech innovations. For readers following the health sector, here is Pluang's market snapshot as of Oct 14, 2026 19:01 WIB: Among 150 priced health-sector US stocks, 105 rose and 40 fell. Novartis AG (NVS) traded at USD 144.94 with a 1-day gain of 1.78% and a typical hold time of 82 days, contrasting with Sana Biotechnology Inc (SANA) at USD 2.45, up 1.66% with a much shorter hold time of 23 days, while Quest Diagnostics Inc (DGX) declined 1.52% to USD 227.06 but saw 100% buy order activity on Pluang.
Genesis Global won the Best AI Solution for Software Development award at the 2026 AI in Capital Markets Awards for its product Genesis Create. This software combines AI with reusable components and financial expertise to help firms develop productio...
nuVizz has been recognized as an Accelerator in the 2026 Nucleus Research Transportation Management Value Matrix for its specialized last-mile delivery technology. The platform excels in coordinating complex delivery networks involving private fleets...
ASML Holding posted a strong Q3 2026 earnings per share of $14.65, beating estimates of $12.17, driven by a 55% year-over-year sales growth and a 57.5% gross margin. Although revenue was slightly below expectations at $13.05 billion, the company bene...
Charles Schwab is set to report its Q3 2026 earnings with an estimated EPS of $1.66 and revenue around $7.18-$7.19 billion, reflecting significant growth driven by an 18.2% increase in trading revenue, net interest income, and asset management fees. ...
Transmission System Operators (TSOs) are increasingly investing in software like Energy Management Systems and grid planning tools to modernize aging infrastructure, enhance cybersecurity, and expand grid capacity. Cybersecurity remains their top con...
